Mass Spectrometry Imaging of atherosclerosis-affine Gadofluorine following Magnetic Resonance Imaging

Fabian Lohöfer, Rebecca Buchholz, Almut Glinzer, Katharina Huber, Helena Haas, Georgios Kaissis, Annette Feuchtinger, Michaela Aichler, Peter B Sporns, Carsten Höltke, Miriam Stölting, Franz Schilling, René M Botnar, Melanie A Kimm, Cornelius Faber, Axel K Walch, Alma Zernecke, Uwe Karst, Moritz Wildgruber

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)
90 Downloads (Pure)


Molecular imaging of atherosclerosis by Magnetic Resonance Imaging (MRI) has been impaired by a lack of validation of the specific substrate responsible for the molecular imaging signal. We therefore aimed to investigate the additive value of mass spectrometry imaging (MSI) of atherosclerosis-affine Gadofluorine P for molecular MRI of atherosclerotic plaques. Atherosclerotic Ldlr-/- mice were investigated by high-field MRI (7 T) at different time points following injection of atherosclerosis-affine Gadofluorine P as well as at different stages of atherosclerosis formation (4, 8, 16 and 20 weeks of HFD). At each imaging time point mice were immediately sacrificed after imaging and aortas were excised for mass spectrometry imaging: Matrix Assisted Laser Desorption Ionization (MALDI) Imaging and Laser Ablation - Inductively Coupled Plasma - Mass Spectrometry (LA-ICP-MS) imaging. Mass spectrometry imaging allowed to visualize the localization and measure the concentration of the MR imaging probe Gadofluorine P in plaque tissue ex vivo with high spatial resolution and thus adds novel and more target specific information to molecular MR imaging of atherosclerosis.

Original languageEnglish
Article number79
JournalScientific Reports
Issue number1
Early online date9 Jan 2020
Publication statusPublished - Jan 2020


Dive into the research topics of 'Mass Spectrometry Imaging of atherosclerosis-affine Gadofluorine following Magnetic Resonance Imaging'. Together they form a unique fingerprint.

Cite this